RU2011123655A - Полностью гуманизированные антитела против n-кадгерина - Google Patents

Полностью гуманизированные антитела против n-кадгерина Download PDF

Info

Publication number
RU2011123655A
RU2011123655A RU2011123655/10A RU2011123655A RU2011123655A RU 2011123655 A RU2011123655 A RU 2011123655A RU 2011123655/10 A RU2011123655/10 A RU 2011123655/10A RU 2011123655 A RU2011123655 A RU 2011123655A RU 2011123655 A RU2011123655 A RU 2011123655A
Authority
RU
Russia
Prior art keywords
cancer
antibody
cadherin
fragment
tissue sample
Prior art date
Application number
RU2011123655/10A
Other languages
English (en)
Russian (ru)
Inventor
Роберт Е. Райтер
Эрик ЛЁПЕН
Анна М. ВУ
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of RU2011123655A publication Critical patent/RU2011123655A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
RU2011123655/10A 2008-11-10 2009-11-10 Полностью гуманизированные антитела против n-кадгерина RU2011123655A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11304208P 2008-11-10 2008-11-10
US61/113,042 2008-11-10
PCT/US2009/063881 WO2010054377A2 (en) 2008-11-10 2009-11-10 Fully human antibodies against n-cadherin

Publications (1)

Publication Number Publication Date
RU2011123655A true RU2011123655A (ru) 2012-12-20

Family

ID=42153647

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011123655/10A RU2011123655A (ru) 2008-11-10 2009-11-10 Полностью гуманизированные антитела против n-кадгерина

Country Status (13)

Country Link
US (2) US8703920B2 (enExample)
EP (1) EP2356145A4 (enExample)
JP (1) JP2012508027A (enExample)
KR (1) KR20110084309A (enExample)
CN (1) CN102300873A (enExample)
AU (1) AU2009313239A1 (enExample)
BR (1) BRPI0921457A2 (enExample)
CA (1) CA2743122A1 (enExample)
CO (1) CO6362022A2 (enExample)
IL (1) IL212795A0 (enExample)
MX (1) MX2011004945A (enExample)
RU (1) RU2011123655A (enExample)
WO (1) WO2010054377A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EP2004230A4 (en) * 2006-03-21 2009-05-20 Univ California N-CADHERINE AND LY6 E: OBJECTIVES FOR CANCER DIAGNOSIS AND THERAPY
EA201001603A1 (ru) * 2008-04-04 2011-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin
GB201119089D0 (en) 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders
CN104203280A (zh) 2012-03-27 2014-12-10 诺华股份有限公司 纤维化的治疗
US10125780B2 (en) * 2014-08-21 2018-11-13 Johnson Controls Technology Company Battery monitoring system
US20200165351A1 (en) * 2017-06-06 2020-05-28 The Regents Of The University Of California Humanized anti-n-cadherin antibodies and uses thereof
KR20240007939A (ko) * 2021-05-13 2024-01-17 우시 바이올로직스 아일랜드 리미티드 항-p-카드헤린 항체를 포함하는 항체 콘쥬게이트 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889157A (en) 1990-10-12 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Humanized B3 antibody fragments, fusion proteins, and uses thereof
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
AU2001249064A1 (en) 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
AU2004242845B2 (en) * 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EP2004230A4 (en) 2006-03-21 2009-05-20 Univ California N-CADHERINE AND LY6 E: OBJECTIVES FOR CANCER DIAGNOSIS AND THERAPY
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
EA201001603A1 (ru) 2008-04-04 2011-06-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитела против кадгерина, блокирующие рост опухоли, ангиогенез и метастазирование
US8703920B2 (en) 2008-11-10 2014-04-22 The Regents Of The University Of California Fully human antibodies against N-cadherin

Also Published As

Publication number Publication date
IL212795A0 (en) 2011-07-31
US20140017240A1 (en) 2014-01-16
WO2010054377A9 (en) 2011-02-03
BRPI0921457A2 (pt) 2016-01-12
JP2012508027A (ja) 2012-04-05
EP2356145A2 (en) 2011-08-17
US20100233170A1 (en) 2010-09-16
MX2011004945A (es) 2011-11-01
WO2010054377A3 (en) 2010-09-16
US8703920B2 (en) 2014-04-22
WO2010054377A2 (en) 2010-05-14
EP2356145A4 (en) 2012-07-18
CO6362022A2 (es) 2012-01-20
KR20110084309A (ko) 2011-07-21
CA2743122A1 (en) 2010-05-14
AU2009313239A1 (en) 2011-07-07
CN102300873A (zh) 2011-12-28

Similar Documents

Publication Publication Date Title
Hemmerlein et al. Overexpression of Eag1 potassium channels in clinical tumours
US9823251B2 (en) Anti-Uroplakin II antibodies systems and methods
JP2022028918A5 (enExample)
RU2015104579A (ru) Диагностические анализы и наборы для детекции фолатного рецептора 1
US9816997B2 (en) Anti-SOX10 antibody systems and methods
RU2014149332A (ru) Антитела против клаудина 18.2 для диагностики рака
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
HRP20110171T1 (hr) Postupak za predviđanje reakcije na liječenje inhibitorom her dimerizacije
RU2013142334A (ru) КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ ДЛЯ ОПРЕДЕЛЕНИЯ НЕ4а
KR20110090985A (ko) 인간 ｃｘｃｌ１ 단백질의 면역학적 측정 방법
RU2013104137A (ru) Изоформы bard1 при раке легкого и колоректальном раке и их применение
RU2019110953A (ru) Моноклональное антитело, специфически связывающееся с тиоредоксином-1, и его применение
CN116410322A (zh) 抗人pcdh7蛋白的单克隆抗体及其应用
JP2013533865A5 (enExample)
US8257716B2 (en) Anti-PDEF antibodies and uses thereof
CN101302254A (zh) 抗肝癌源性生长因子单克隆抗体及其应用
AU2011298090A1 (en) Antibody against colorectal cancer marker
KR20120134547A (ko) 항-ａｔｉｃ 자가면역항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
JP2018520366A5 (enExample)
CN118339455A (zh) 调节性t细胞的生物标志物
US20090175871A1 (en) Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors
DK1541676T3 (da) Mod prothrombin-fragment F1 2 rettede abtistoffer, deres fremstilling og anvendelse
CN121426957B (zh) 一种抗Nectin-4蛋白单克隆抗体及其相关产品和用途
WO2022241752A1 (zh) 特异结合电压门控钠离子通道α亚基Nav1.7的抗体或抗体片段
CN121494980A (zh) 抗胃泌素抗体及其杂交瘤细胞株和应用